Angiotensin II Stimulation of NAD(P)H Oxidase Activity

Circulation Research - Tập 91 Số 5 - Trang 406-413 - 2002
Puvi Seshiah1, David S. Weber1, Petra Ročić1, Liisa Valppu1, Yoshihiro Taniyama1, Kathy K. Griendling1
1From the Division of Cardiology, Emory University, Atlanta, Ga.

Tóm tắt

Angiotensin II (Ang II)–stimulated hypertrophy of vascular smooth muscle cells is mediated by reactive oxygen species (ROS) derived from NAD(P)H oxidases. The upstream signaling mechanisms by which Ang II activates these oxidases are unclear but may include protein kinase C, tyrosine kinases, phosphatidylinositol-3-kinase, and Rac, a small molecular weight G protein. We found that Ang II–stimulated ROS production is biphasic. The first phase occurs rapidly (peak at 30 seconds) and is dependent on protein kinase C activation. The larger second phase of ROS generation (peak at 30 minutes) requires Rac activation, because inhibition of Rac by either Clostridium difficile toxin A or dominant-negative Rac significantly inhibits Ang II–induced ROS production. Phosphatidylinositol-3-kinase inhibitors (wortmannin or LY294002) and the epidermal growth factor (EGF) receptor kinase blocker AG1478 attenuate both Rac activation and ROS generation. The upstream activator of EGF receptor transactivation, c-Src, is also required for ROS generation, because PP1, an Src kinase inhibitor, abrogates the Ang II stimulation of both responses. These results suggest that c-Src, EGF receptor transactivation, phosphatidylinositol-3-kinase, and Rac play important roles in the sustained Ang II–mediated activation of vascular smooth muscle cell NAD(P)H oxidases and provide insight into the integrated signaling mechanisms whereby Ang II stimulation leads to activation of the growth-related NAD(P)H oxidases.

Từ khóa


Tài liệu tham khảo

10.1161/res.74.6.8187280

10.1074/jbc.271.38.23317

10.1161/hyp.32.3.488

Mohazzab- H, KM, Wolin MS. Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle. Am J Physiol. 1994; 267: L815–L822.

10.1172/JCI118623

10.1161/atvb.20.10.2175

10.1182/blood.V93.5.1464

10.1006/abbi.2001.2642

10.1161/res.88.9.888

10.1161/01.CIR.104.1.79

10.1161/res.86.5.494

10.1042/bj3180379

10.1074/jbc.275.14.10527

10.1152/ajpcell.1999.276.4.C838

10.1161/atvb.22.2.300

10.1161/01.cir.0000014611.28864.1e

10.1161/hyp.34.4.976

10.1016/S0014-2999(99)00357-X

10.1074/jbc.273.15.8890

10.1161/01.atv.21.4.489

10.1046/j.1523-1755.2000.t01-1-00201.x

10.1038/35083070

10.1126/science.279.5350.558

10.1126/science.279.5350.560

10.1016/S0021-9258(18)98644-8

10.1016/0891-5849(94)90129-5

Zeller JM, Rothberg L, Landay AL. Evaluation of human monocyte oxidative metabolism utilizing a flow cytometric assay. Clin Exp Immunol. 1989; 78: 91–96.

10.1097/00004872-199816121-00010

10.1128/MCB.16.12.7115

10.1074/jbc.274.19.13198

Lassègue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, Griendling KK. Angiotensin II down-regulates the vascular AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol. 1995; 48: 601–609.

Aktories K, Schmidt G, Just I. Rho GTPases as targets of bacterial protein toxins. Biol Chem. 2000; 381: 421–426.

10.1074/jbc.274.32.22699

10.1161/res.81.2.249

10.1161/res.87.12.1195

10.1089/ars.1999.1.2-167

10.1038/sj.bjp.0704356

10.1038/sj.bjp.0704314

10.1002/jlb.67.3.396

10.1074/jbc.M102124200

10.1016/S0968-0004(00)01658-3

Laragh JH Sealy JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis.In: Laragh JH Brenner BM eds. Hypertension: Pathophysiology Diagnosis and Management. New York NY: Raven Press; 1990: 1329–1348.

10.1056/NEJM200001203420301

Thông tin
Thông tin xuất bản

Circulation Research

Tập 91 Số 5

406-413

Thông tin tác giả